SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Published:2019-02-15 Issue:2 Volume:10 Page:114-132
ISSN:1948-9358
Container-title:World Journal of Diabetes
language:
Short-container-title:WJD

Author:

Raj Henith,Durgia Harsh,Palui Rajan,Kamalanathan Sadishkumar,Selvarajan Sandhiya,Kar Sitanshu Sekhar,Sahoo Jayaprakash

Publisher

Baishideng Publishing Group Inc.

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference38 articles.

1. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms

2. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification

3. Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo

4. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

5. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease;Metabolism and Target Organ Damage;2024-07-29

2. “Adjusting internal organs and dredging channelon” electroacupuncture glycolipid metabolism disorders in NAFLD mice by mediating the AMPK/ACC signaling pathway;Diabetology & Metabolic Syndrome;2024-07-25

3. Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting;European Cardiology Review;2024-05-09

4. Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus;Cureus;2024-02-07

5. Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities, and Management of Non-alcoholic Fatty Liver Disorder;Current Drug Therapy;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3